title: Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Arjun
authors.initials: A
authors.lastname: Gupta
authors.affiliation: Department of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Jan
authors.initials: J
authors.lastname: Petrasek
authors.affiliation: Department of Hematology Oncology, MD Anderson Cancer Center, Houston, TX.
authors.forename: Shiraj
authors.initials: S
authors.lastname: Sen
authors.affiliation: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Purva
authors.initials: P
authors.lastname: Gopal
authors.affiliation: Department of Hematology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: harris.naina@utsouthwestern.edu.
authors.forename: Harris V
authors.initials: HV
authors.lastname: Naina
mesh_terms: D000328:Adult; D000368:Aged; D000079963:Brentuximab Vedotin; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: Anti CD-30; Chemotherapy; Hepatic impairment; Liver failure; Lymphoma